
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Argent Biopharma Limited | LSE:RGT | London | Ordinary Share | AU0000326647 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.00 | 5.00 | 7.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:5958N ReGen Therapeutics PLC 16 July 2003 ReGen Therapeutics Plc Embargoed until 7am 16 July 2003 ReGen Therapeutics Plc SUBSTANTIAL SHAREHOLDING London, UK - 16 May, 2003: ReGen Therapeutics Plc (the "Company") announces that on 15 July 2003 it received notification from Mr Colin Blackbourn that he is beneficially interested in 7,000,000 ordinary shares of the Company representing 3.1% of the current issued share capital of the Company. For further information, please contact: Andrew Marshall Marshall Robinson Roe Tel No 020 7489 2033 This information is provided by RNS The company news service from the London Stock Exchange END HOLEAXXSFDLDEFE
1 Year Argent Biopharma Chart |
1 Month Argent Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions